Key result
Clinicogenomic machine learning models predict 30-day hospital readmissions for lung, breast, and colon cancer.
Why the study?
The study was conducted to curate high-quality clinical and genomic datasets from patients with cancer to predict hospital readmission using machine learning models.
Can machine learning models using clinicogenomic data predict hospital readmission in patients with cancer?
Observational
No
Can machine learning models using clinicogenomic data predict hospital readmission in patients with cancer?
Standard machine learning models integrating clinical and genomic data can successfully predict hospital readmission in cancer patients.
Hypothesis-generating for ML-based readmission prediction in common cancers; leaves open prospective validation before clinical adoption.
PURPOSE Curating high-quality clinical and genomic data sets from patients with cancer to predict hospital readmission using machine learning (ML) models. METHODS We extracted data from electronic health records for patients with cancer in the University of California, San Diego Health System, to curate clinicogenomic data sets for lung, breast, and colon cancers. We constructed ML models to predict the risk of hospital readmission 30, 60, and 90 days postdischarge. Standard ML models (logistic regression, random forest [RF], gradient boosting [GB], neural network) and multitask neural network models were developed to simultaneously predict all three readmission outcomes. RESULTS Our results revealed that rehospitalization is most frequent in colon cancer within 30 days. For the 30-day hospitalization prediction, GB achieved the highest area under the precision recall curve (PR-AUC) for lung (0.415) and breast (0.470) cancers and RF achieved the overall highest PR-AUC for colon cancer (0.621). Explainability analysis revealed that health care metrics (such as the number of previous admissions and average length of stay), risk scores composed of diagnosis codes, and treatments are significant features in predicting readmission within cancer types. It also identified EGFR mutations as a potential predictor of readmission in colon cancer. CONCLUSION The study highlights the potential of integrating clinical and genomic data for predicting adverse outcomes in patients with cancer. The standard ML approaches were able to successfully capture patterns in readmission and outperformed the more complex models. Limitations include the relatively small data set from a single institution. Ultimately, this study highlights the value of curating and maintaining clinicogenomic information at an institution level to streamline data set curation and model development.
No takes yet. Share an insight, caveat, or question.
Kalahasti et al. (2026) conducted an observational in Lung, breast, and colon cancers. Standard machine learning models (logistic regression, random forest, gradient boosting) vs. Complex multitask neural network models was evaluated on Hospital readmission at 30, 60, and 90 days postdischarge. Standard machine learning models predicted 30-day hospital readmissions using clinicogenomic data, achieving PR-AUCs of 0.415 (lung), 0.470 (breast), and 0.621 (colon cancer).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: